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Transposable elements (TEs) are notable drivers of
genetic innovation. Over evolutionary time, TE
insertions can supply new promoter, enhancer, and
insulator elements to protein-coding genes and
establish novel, species-specific gene regulatory
networks. Conversely, ongoing TE-driven insertional
mutagenesis, nonhomologous recombination, and
other potentially deleterious processes can cause
sporadic disease by disrupting genome integrity or
inducing abrupt gene expression changes. Here, we
discuss recent evidence suggesting that TEs may
contribute regulatory innovation to mammalian
embryonic and pluripotent states as a means to ward
off complete repression by their host genome.mobile genetic elements are found in every eukaryoticBackground
Mammalian embryonic development is governed by a
complex set of genetic and epigenetic instructions. This
genomic blueprint undergoes evolutionary selection and,
as such, the fundamental order of development is well
conserved among mammals. At fertilization, sperm and
egg unite to form the zygote, which undergoes succes-
sive cleavage divisions, yielding two-, four-, and eight-
cell embryonic stages [1, 2]. Initially, the zygotic genome
is transcriptionally inactive, with maternally inherited
factors regulating embryonic metabolism and develop-
ment. Embryonic genome activation occurs at around
the eight-cell stage in humans and the two-cell stage in
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daughter cells are totipotent; that is, they have the poten-
tial to differentiate into all embryonic and extraembryonic
cell types. During development, the differentiation poten-
tial of embryonic cells becomes progressively more re-
stricted. At the blastocyst stage, the cells of the inner cell
mass (ICM) are pluripotent, meaning that while they can-
not give rise to extraembryonic tissues, they can generate
all cell lineages and are able to self-renew. Hence, early de-
velopment involves rapid cellular diversification driven by
myriad, and largely still undefined, transcriptional and epi-
genetic programs (Box 1).
Pluripotent states arising embryonically in vivo, or
achieved in vitro by cellular reprogramming, are associ-
ated with epigenetic derepression and transcriptional ac-
tivation of transposable elements (TEs) [4–6]. These
genome sequenced to date and account for at least half
of mammalian DNA [7–9]. In most mammals, retrotran-
sposons are the predominant TEs. These can be divided
into long terminal repeat (LTR) retrotransposons, in-
cluding endogenous retroviruses (ERVs), and non-LTR
retrotransposons such as long interspersed elements
(LINEs) and short interspersed elements (SINEs) (Fig. 1a)
[10–12]. LINE-1 (L1; Box 2), and ERV families are the
only autonomous retrotransposons identified in the hu-
man and mouse genomes, though, importantly, human
ERVs (HERVs) are all likely now retrotransposition in-
competent (Box 3).
All retrotransposons mobilize via a “copy-and-paste”
mechanism involving a transcribed RNA intermediate
that is reverse transcribed and integrated as a nascent
cDNA into genomic DNA. However, there are essential
differences in the retrotransposition mechanisms used
by LTR and non-LTR retrotransposons (Fig. 1b, c). L1
mRNA transcription relies on an internal 5′ promoter,
whereas ERV proviruses utilize a 5′ LTR promoter for
transcription initiation (Fig. 1a). Crucially, most new L1is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Box 1. Regulatory networks controlling pluripotency
Programmed shifts in transcriptional and epigenetic states
during embryogenesis have been studied primarily using
in vitro systems. Embryonic stem cells (ESCs) are pluripotent
cells derived from the blastocyst inner cell mass. Cultured ESCs
are intensively used to study pluripotency, particularly in humans.
Over the past decade, a core regulatory circuit incorporating the
transcription factors Oct4 (also known as Pou5f1), Sox2, and
Nanog [126–128] has been revealed to regulate ESC pluripotency
[129]. This circuit activates pluripotency-associated factors and
represses lineage-specific genes [130]. Pluripotent cells can also be
derived in vitro via somatic cell reprogramming. Induced
pluripotent stem cells (iPSCs) were initially produced by forced
expression of Oct4, Sox2, Klf4, and c-Myc using retroviral
vectors [131, 132]. Numerous methods have since been developed
to improve reprogramming efficiency and iPSC safety [133]. As for
ESCs, iPSCs provide a powerful system to understand the
pluripotent state and can differentiate to all cell types of the
body [131, 132]
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L1 regulatory sequence. Of 500,000 human L1 copies,
only about 7000 retain the canonical 5′ promoter [7, 13].
By contrast, about 90 % of HERVs exist in the genome as
solitary LTRs due to recombination of proviral 5′ and 3′
LTRs [11, 14]. Many of these LTRs maintain, or restore
through acquired mutations, their natural transcriptional
and regulatory signatures, which can perturb the expres-
sion of nearby genes [15]. While the regulatory capacity of
older LTRs will tend to diminish over time, the approxi-
mately 440,000 identifiable LTRs in the human genome
[7] still carry enormous potential to regulate genes and
gene networks [14–17]. Therefore, compared with L1,
ERVs are arguably a much greater source of regulatory
innovation (Fig. 2).
Recent studies have revealed a complex and somewhat
paradoxical interplay between retrotransposons and their
host genome in pluripotent cells. On one hand, retro-
transposons have long been regarded as fundamentally
selfish genetic elements [18] that, to ensure their sur-
vival, must evade host genome surveillance and mobilize
in cells that provide opportunities for germline transmis-
sion. Transcriptional reactivation of retrotransposons in
the early mammalian embryo aligns with this evolutionary
imperative, despite retrotransposition posing a threat to
genome integrity. Indeed, cells employ numerous mecha-
nisms to restrict retrotransposition at this stage [19–23].
On the other hand, transcription from ERV promoters
drives the expression of cellular genes as well as ERV-
derived sequences and appears to be a fundamentalcharacteristic of the pluripotent state [16, 24–31]. LTRs
may be permitted to thrive in this environment due to the
materials they provide to the host genome for regulatory
network innovation (Fig. 3). Indeed, as well as providing
alternative promoters to pluripotency genes [28], ERVs
can serve as long-range enhancers [26], produce regula-
tory noncoding RNAs [27, 30], and may, in some cases,
express their own viral proteins [29, 31]. Hence, tran-
scribed products arising from ERVs may promote, or even
be required for, the pluripotent state [24–33]. Finally, re-
ports of L1 retrotransposition in somatic cells have fueled
speculation that TE-derived mosaicism may lead to func-
tional innovation during development [34–37].
Here, we review the restraint and activity of TEs in
embryonic cells and later in development, as well as the
unexpected promotion of pluripotent states by ERVs.
We further appraise the convergent contributions to em-
bryogenesis made by ERVs in distinct mammalian clades
as evidence of an evolved strategy to avoid, or at least
delay, host genome repression.
ERV-driven transcription in the early embryo
ERV regulation of protein-coding genes
Although there are spectacular examples of TE proteins
underpinning functional innovation, such as in the pla-
centa [38], regulatory sequences exapted from TEs argu-
ably loom larger in our evolutionary history [15]. Indeed,
up to 30 % of human and mouse transcription start sites
(TSSs) are situated in TEs and display tissue-specific
expression patterns [33, 39]. Embryonic human tissues
express the greatest diversity of TE-associated TSSs ob-
served to date [33], highlighting the potential of TEs to
drive cell type and developmental stage-specific expres-
sion, particularly during early embryogenesis when the
genome becomes demethylated [40]. In mouse, the
LTR promoters of MuERV-L elements regulate a net-
work of genes critical for totipotency and specific to
the two-cell stage of embryonic development [41]. TE-
derived regulatory sequences likewise contribute to the
evolution of regulatory networks in pluripotent stem
cells. For example, only about 5 % of Oct4 and Nanog
transcription factor (TF) binding sites are shared in
mouse and human embryonic stem cells (hESCs). TEs
contribute a significant proportion (about 25 %) of the
remaining, species-specific, binding sites [42]. More-
over, in vitro knockdown of specific ERVs via RNA
interference can lead to a reduction in pluripotency
markers [24, 26–28, 43–46]. Thus, TE sequences are
broadly and strongly transcribed in the early embryo
and can influence pluripotency by being exapted into,
or at least adding robustness to, pluripotency net-
works. These findings underscore the universality and
versatility of TEs in driving the evolution of regulatory
networks.
Fig. 1 Long terminal repeat (LTR) and non-LTR retrotransposition mechanisms. a Mammalian retrotransposon structures. A long interspersed element
(LINE; human L1 shown) typically consists of a 5′ untranslated region (UTR; blue box) harboring an internal promoter, two open reading frames
(ORF1, ORF2), a 3′ UTR (small blue box), and a poly(A)-tail. A short interspersed element (SINE; mouse B1 shown) does not encode proteins
and is trans-mobilized by LINE proteins. An endogenous retrovirus (ERV), such as mouse intracisternal A-type particle (IAP) and Mus type-D
related retrovirus (MusD), lacks an Env protein but encodes functional Gag and Pol proteins flanked by a LTR at the 5′ (black box) and 3′ (red box)
ends. Arrows indicate transcription start sites. b ERV mobilization starts with mRNA transcription and translation to yield Gag and Gag–Pro–Pol
fusion proteins. The fusion proteins consist of a Gag protein (Gag), a protease (Pr), an integrase (In), and a reverse transcriptase (RT). Gag proteins
build a virus-like particle and encapsulate the fusion proteins, which are processed into separate mature proteins. The ERV mRNA is then reverse
transcribed, generating a cDNA. This cDNA and the integrase build a preintegration complex. The integrase then creates a double-strand DNA
break, followed by genomic integration of a new ERV copy. Target site duplications (TSDs) are indicated by blue triangles. c L1 mobilization begins
with transcription of an L1 mRNA, which is translated to yield ORF1p and ORF2p. ORF1p, ORF2p, and the L1 mRNA form a ribonucleoprotein
particle that re-enters the nucleus. The ORF2p endonuclease cleaves the first genomic DNA strand, while its reverse transcriptase uses a now free
3′ OH group as a primer for reverse transcription of the L1 mRNA. Following second-strand DNA cleavage, a new L1 copy is integrated into the
genome and is typically flanked by TSDs
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Box 2. L1 retrotransposons
The non-long terminal repeat retrotransposon long interspersed element-1 (L1) is the only autonomous, mobile human transposable
element [10, 12, 116, 134]. L1 occupies approximately 17 % of the human genome [7]. L1 also mobilizes Alu and SINE–VNTR–Alu (SVA)
elements in trans [135, 136]. Mice, by contrast, have three L1 subfamilies (TF, GF, and A) that are autonomous, as well as nonautonomous
short interspersed elements (SINEs) retrotransposed by L1 [10]. L1 accounts for 19 % of the mouse genome [8]. A full-length human L1 is
approximately 6 kb long and initiates mRNA transcription from a 5′ sense promoter active in gametes, stem cells, and various somatic
tissues [33, 36, 48, 71, 137–139]. The bicistronic L1 mRNA encodes two proteins, ORF1p and ORF2p, which are flanked by 5′ and 3′
untranslated regions (Fig. 1a). An L1 antisense peptide (ORF0p) [56] can also be expressed by an adjacent L1 antisense promoter [115].
This antisense promoter is expressed in many spatiotemporal contexts, including in stem cells, and can provide alternative
promoters to protein-coding genes [33, 56, 115, 140]. L1 ORF2p presents endonuclease [141] and reverse transcriptase [142] activities
and, during retrotransposition, L1 ORF1p, ORF2p, and the canonical L1 mRNA associate in cis to form a cytoplasmic ribonucleoprotein
particle (RNP) [143]. The RNP can then enter the nucleus, where the ORF2p endonuclease cleaves genomic DNA, and the ORF2p reverse
transcriptase synthesizes a new L1 copy at the cleavage site using the L1 mRNA as a template. This process is called target-site primed
reverse transcription (TPRT) [144] (Fig. 1c).
The L1 5′ promoter is the major focus of host genome efforts to prevent L1 mobility, through DNA methylation and transcription factor
repression and other pathways [145, 146]. Thus, it appears that L1 in the main persists as a mobile element by avoiding detection of its
5′ promoter by host genome surveillance pathways and, where this fails, by harnessing new promoter structures [13]. This could
explain the exceptional L1 5′ promoter diversity observed even among closely related primates [23]. It should also be noted that
the vast majority of L1 copies in the genome are 5′ truncated and lack the 5′ promoter [13], meaning that the host factors guarding
against full-length L1 transcription are not necessarily able to recognize truncated L1s.
Box 3. Endogenous retroviruses
Endogenous retroviruses (ERVs) are derived from exogenous retroviruses that, at some point, infected an individual organism’s germ
cells, integrated into their genome, and were subsequently inherited by their offspring. ERVs are divided into class I, class II, and class III
elements, based on the exogenous virus class that they are most similar to [11]. Full-length ERVs are 5–10 kb in length, encode proteins
important for mobilization, and are flanked by two identical long terminal repeats (LTRs; 300–1000 bp) that regulate ERV transcription.
Loss of the env gene, found in exogenous retroviruses, is a common feature of ERVs as they adopt an intracellular life cycle as a
retrotransposon [11, 147, 148]. ERV retrotransposition is initiated by the transcription of the 5′ LTR and terminates in the 3′ LTR,
generating a terminally redundant mRNA that is translated into Gag and Gag–Pro–Pol fusion proteins. Gag proteins encapsulate
the mRNA and fusion protein. Pro has protease activity whereas Pol possesses reverse transcriptase, ribonuclease, and integrase
domains that generate independent proteins by proteolytic maturation. Together they produce a double-stranded cDNA copy of the
ERV and flanking LTRs. This cDNA is then integrated into the genome by the ERV integrase [149] (Fig. 1b).
Human endogenous retroviruses (HERVs) comprise about 8 % of the human genome [7]. All HERVs are considered to be now
retrotransposition incompetent [150, 151]. The HERV-K (HML-2) family is exceptional, with several members arising after the divergence of
humans and chimpanzees (approximately 6 million years ago) and a handful of polymorphic HERV-K insertions found in human populations
[152–155]. Although a mobile HERV-K element has yet to be identified in humans, it is possible that rare, as yet undiscovered polymorphic
elements could retain retrotransposition competence [152]. In contrast to humans, ERVs account for approximately 10 % of the mouse
genome [8]. Several mouse ERV families are still autonomously active, including intracisternal A-type particle elements [106], Moloney
murine leukemia virus [156], and Mus type-D related retrovirus (MusD) [147] elements, as well as the MusD-dependent early retrotransposon
family [157]. Together, new mouse ERV insertions are responsible for about 10 % of documented germline mutations in inbred strains [106].
Clade-specific ERVs also occur in other mammals, although genomic ERV content varies significantly between species [11]. Numerous
instances of mammalian ERVs contributing regulatory sequences to genes, including examples of convergent evolution [158], are found in
pluripotent cells and elsewhere [15, 159, 160].
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L1
~90% of new L1 copies are
5′ truncated and lack the promoter





Fig. 2 Long interspersed element 1 (L1) and endogenous retrovirus
(ERV) regulatory impact post-integration. Most L1 copies are 5′
truncated (left) and lack the sense and antisense L1 promoters
located in the 5′ untranslated region (large blue box). As a result,
these L1 insertions have less capacity to drive chimeric transcription
with neighboring genes. ERV insertions (right) remain either full-length,
with flanking 5′ (black box) and 3′ long terminal repeats (LTRs; red box)
that potentially retain promoter function, or, more commonly,
recombine between the LTRs to form a solitary LTR, which retains
the promoter/enhancer region. Arrows indicate putative transcription
start sites
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pluripotent state
ERV transcription independent of protein-coding genes
has also been linked to pluripotency. Despite an appar-
ent lack of retrotransposition activity, specific HERVs
are actively transcribed in hESCs and are thought to in-
fluence pluripotency maintenance [24, 25, 27–32, 47].
The HERV families HERV-H and HERV-K (HML-2) in
particular appear to be connected to early human em-
bryonic development [25, 31]. While stochastic tran-
scriptional derepression of various HERVs [47] as well as
non-LTR retrotransposons [48] in pluripotent cells can
probably be attributed to a general relaxation of TE si-
lencing [40], specific classes of elements are consistently
reactivated across hESC lines, indicating that their ex-
pression can serve as a marker for an undifferentiated
state [28, 29], further raising the possibility that these el-
ements have a functional link to pluripotency. Distinct
HERV families also denote specific embryonic stages,
suggesting HERV expression profiles may signify cell
identity [25]. It is important to note, however, that, in
many cases, only a small fraction of HERVs from a spe-
cific family are transcribed [25] and that their genomic
context likely plays a pivotal role in their expression.
The reasons for HERV families presenting distinct ex-
pression patterns during early embryogenesis are cur-
rently unclear. To speculate, such patterns could be a
reflection of the optimal “ecological niche” of their an-
cestral exogenous counterparts and may mimic the par-
allel expression patterns of LTR-binding TFs.Human oocytes and zygotes (to the cell–cell stage)
contain the highest percentages of HERV transcripts ob-
served during development; these are almost certainly
deposited maternally prior to embryonic genome activa-
tion [25]. Abundant transcription emanating from MaLR
and ERVK LTRs has also been documented for mouse
oocytes [5, 49]. The provision of ERV transcripts by the
maternal genome supports ERV functionality in the early
embryo, as these RNAs already seem to be necessary be-
fore the embryonic genome is able to generate its own
transcripts [31]. However, it is also possible that ERV
transcripts do not have a specific function at this early
stage but their maternal deposition is permitted because
they do not harm the developing embryo. Nevertheless,
stage-specific expression from ERV promoters, and of
protein-coding genes, LTR-driven chimeric transcripts,
and ERV transcripts proper, is a defining feature of early
mammalian development.
Regulation of HERV-K and HERV-H by
pluripotency factors
As well as gene regulation transacted by ERVs, many
studies have revealed how ERVs are in turn regulated by
pluripotency genes. For instance, the core pluripotency
TFs Oct4 and Nanog (Box 1) bind specific HERV fam-
ilies (Fig. 3) [26, 42]. HERV-K is the most recently active
HERV family and many HERV-K copies retain their
protein-coding potential [50]. Notably, transcription
from the youngest subclass of HERV-K is induced from
its LTR, known as LTR5HS (for “human-specific”), at
the eight-cell stage, during embryonic genome activa-
tion, and continues through to the blastocyst stage
(Fig. 4a). LTR5HS contains an Oct4-binding motif that is
not present in older LTRs such as LTR5a or LTR5b [31].
DNA hypomethylation and transactivation by Oct4 at
LTR5HS synergistically stimulate HERV-K expression
and lead to the presence of retroviral and viral-like parti-
cles in human preimplantation embryos [31]. HERV-K
type 2 proviruses encode the protein Rec, which derives
from alternative splicing of the env gene and is respon-
sible for nuclear export and translation of viral RNAs
[51]. Rec can be found in pluripotent cells and may in-
fluence expression of the interferon-induced viral re-
striction factor IFITM1 in epiblast cells [31, 52].
Consequently, Grow et al. [31] suggested that antiviral
responses might be induced by HERV-K proteins, pro-
tecting the human embryo against new retroviral infec-
tions. Similarly, HERV-K type 1 proviruses encode the
protein Np9, which is the product of a new alternative
splicing event and coincides with a deletion in the env
region [53, 54]. Interestingly, Rec and Np9 are not
encoded in rodent ERVs, making them a distinguishing
feature of primate ERVs and, moreover, hESCs specific-































Rewiring of gene regulatory networks
Fig. 3 Examples of endogenous retrovirus (ERV) contributions to pluripotency. A long terminal repeat (LTR) possesses binding sites for pluripotency
transcription factors (TFs) and can serve as a transcription start site (TSS). LTRs bound by pluripotency TFs can thereby impact embryonic stem cell
identity by: (1) serving as alternative promoters for pluripotency genes, (2) providing long-range enhancers to specific host genes, (3) generating stem-
cell-specific long noncoding RNAs that can bind to proteins regulating the pluripotent state, (4) transcribing proviral DNA elements as precursors to
ERV protein expression, and (5) rewiring gene regulatory networks by controlling several pluripotency genes
Gerdes et al. Genome Biology  (2016) 17:100 Page 6 of 17therefore, to speculate, as per Grow et al. [31], that
hESCs allow expression of these HERV-K proteins to
fulfill a protective function via, for example, Rec-induced
inhibition of viral infection. It is also possible that some
HERV-K elements fortuitously escape silencing and
manufacture viral proteins as innocuous byproducts of
HERV-K transcription in hESCs (Fig. 3).
HERV-H is another primate-specific retrotransposon
[55] with a potentially important role in the maintenance
of hESC identity and pluripotency (Table 1). HERV-H
transcripts are expressed in pluripotent cells at levels
much higher than those seen in differentiated cells and,
as a result, HERV-H expression is a proposed marker for
pluripotency [28]. Interestingly, HERV-H is expressed in
some induced pluripotent stem cell (iPSC) lines (Box 1)
at higher levels than for other iPSC lines and embryonic
stem cells (ESCs) [47]. Developmental HERV-H expres-
sion also appears to be cell type and stage specific
in vivo (Fig. 4a). For instance, HERV-H and its flanking
LTR element LTR7 can only be detected in epiblast cells
[25], whereas other related LTR variants that flankHERV-H (LTR7B and LTR7Y) are detectable at the
eight-cell stage and morula [25]. LTR7 incorporates
Oct4, Nanog, Klf4, and Lbp9 TF binding sites, which to-
gether appear to mediate HERV-H transcriptional activa-
tion [28]. Once activated, individual LTR7 copies can
generate noncoding RNAs [43] and form chimeric tran-
scripts with protein-coding genes, in some cases supply-
ing multiple promoters to the same gene (Fig. 3) [27, 28,
56]. LTR7 may also be bound by factors central to so-
called naïve, or ground state, pluripotency where cells
are predisposed to self-renew and lack differentiation
markers, showing that ERVs may be involved in fine tun-
ing stem cell phenotype [28, 57]. In sum, HERV-K and
HERV-H are clearly activated by pluripotency TFs and
their expressed products are, at the very least, markers
of pluripotency.
HERV-derived long noncoding RNAs regulate
pluripotency networks
Long noncoding RNAs (lncRNAs) are RNA transcripts
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Fig. 4 Human endogenous retrovirus (HERV) expression patterns in pluripotent cells. a HERV-K transcription in human embryogenesis is initiated
during embryonic genome activation at the eight-cell stage and remains until the blastocyst stage. Dashed lines indicate proposed expression of
HERV-K [31]. HERV-H can only be detected in epiblast cells of the late blastocyst [25]. b After induction of induced pluripotent stem cell (iPSC)
reprogramming, HERV-K and HERV-H are derepressed with distinct dynamics. HERV-K transcription reaches its peak shortly before cells are fully
reprogrammed. HERV-K expression subsequently decreases in reprogrammed cells and is silenced in iPSCs [32]. HERV-H is highly expressed earlier
during reprogramming compared with HERV-K [24]. Note: the time points shown are approximate due to technical differences between studies
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lncRNAs are transcribed antisense to protein-coding
genes or are intergenic [58, 59]. More than two-thirds of
lncRNAs incorporate TE sequences (Fig. 3) and, in cases
such as Xist, a prototypical lncRNA involved in X
chromosome inactivation, TEs are a core component of
lncRNA biogenesis [60, 61]. Other than Xist, and a few
additional examples, lncRNAs have proven difficult to
evaluate functionally because, as well as containing TEs,
lncRNAs are often expressed at very low levels [30].
However, one of the best established lncRNA functions
is to regulate pluripotency, particularly by mediating
changes to chromatin [62, 63]. Interestingly, Au et al.
[64] reported more than 2000 additional long intergenic
noncoding RNA (lincRNA) isoforms, of which 146 were
expressed in hESCs. These human pluripotency-
associated transcripts (HPATs) typically incorporated
ERVs, especially HERV-H [30], and in that regardwere similar to many other hESC-specific lncRNAs
[27, 43, 44, 47]. HPATs appear to contribute to for-
mation of the blastocyst ICM, suggesting an essential
role for HERV-derived lncRNAs in human embryo-
genesis [30].
One particularly interesting lincRNA, HPAT5, is hy-
pothesized to be involved in post-transcriptional gene
regulation: HPAT5 binds AGO2, a core protein catalyz-
ing microRNA (miRNA) processing [65], and the let-7
miRNA family, which modulates hESC pluripotency
[66]. Durruthy-Durruthy et al. [30] have suggested that
HPAT5 controls the balance between pluripotency and
differentiation by negatively regulating let-7 expression.
However, HPAT5 is promoted by the so-called HUERS-
P1 ERV, a low copy number TE that has not been in-
vestigated very deeply in this context. Interestingly, the
HPAT5 promoter is located in the internal Gag se-
quence of the HUERS-P1 ERV, rather than in an LTR.
Table 1 Summary of HERV-H findings to date in human stem cells
Findings Reference(s)
Binding of pluripotency TFs in ESCs and iPSCs within or near LTRs or specific LTR-driven lncRNAs [24, 28, 42–45, 47]
Induction of HERV-H, or LTR7-driven lncRNA/chimeric RNA expression, in ESCs, declining upon differentiation [26–28, 43–45, 47, 60, 161]
Active chromatin marks on specific LTRs in ESCs or iPSCs [28, 32, 43, 44, 47, 162]
DNA hypomethylation at specific LTRs in ESCs [28, 161]
LTR enhancer activity in ESCs [27]
Changes in HERV-H associated with expression changes of genes near LTRs [27, 28, 32, 42]
Induction of HERV-H in iPSCs, declining upon differentiation [24, 27, 28, 32, 46]
Differentiation-defective iPSC clones retain high levels of HERV-H RNA [46]
Knockdown of general HERV-H expression inhibits iPSC formation and causes ESC differentiation [24, 27, 28]
Knockdown of specific LTR-driven RNAs inhibits iPSC formation or causes ESC differentiation [24, 28, 44, 45]
LTR-driven lncRNA acts as miRNA sponge to positively regulate pluripotency TFs [45]
HERV-H RNA associates with coactivators and LTR loci in ESCs [27]
HERV-H expression marks for naïve-like stem cells [28]
HERV-H LTR subtypes expressed sequentially in early development [25, 31]
ESC embryonic stem cell, HERV human endogenous retrovirus, iPSC induced pluripotent stem cell, lncRNA long noncoding RNA, LTR long terminal repeat, miRNA
microRNA, TF transcription factor
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drift or selection, rather than by harnessing the “ready
to use” regulatory motifs found within an LTR. In
addition, the let-7 binding site within HPAT5 occurs
within an imbedded Alu element. HPAT5 is thus an un-
usual, and yet fascinating, example of retrotransposon-
driven regulatory innovation.
More broadly, HERV-driven transcripts contributing
to pluripotency networks unique to humans or primates
are of particular interest. lincRNA-RoR, with its TSS
located in a HERV-H element, represents an excellent
example of a primate-specific TE found to modulate
pluripotency [43]. Notably, lincRNA-RoR is expressed
more highly in iPSCs than in ESCs and can promote
iPSC reprogramming [44], perhaps by serving as an
miRNA sponge protecting Sox2 and Nanog from
miRNA-mediated degradation [45]. In another example,
the gene ESRG, which uses a domesticated HERV-H
promoter, plays a role unique to human pluripotency
[28]. Unusually, ESRG encodes an intact open reading
frame (ORF) in humans, but possibly not in other pri-
mates, and is expressed exclusively in the human ICM
and cultured pluripotent cells [67]. ESRG knockdown
compromises stem cell self-renewal and promotes differ-
entiation, while ESRG overexpression aids reprogram-
ming [28]. These case studies demonstrate recurrent
incorporation of annotated HERV-derived transcripts
into pluripotency networks.
To discover new lncRNAs regulating pluripotency,
Fort et al. [26] surveyed in depth the noncoding tran-
scriptomes of mouse and human stem cells. The result-
ing pluripotency lncRNA catalog included numerous
previously unreported antisense, intergenic, and intronictranscripts that initiate in ERVs. Consistent with an earl-
ier report [33], Fort et al. found an exceptional variety of
stem cell-specific TSSs that are not directly associated
with protein-coding genes. These TSSs often overlap
with TEs, especially with ERVK and MaLR LTR subfam-
ilies in mice and ERV1 in humans, and frequently flank
enhancer elements. In addition to bidirectional tran-
scription denoting enhancer activity [68, 69], TE-derived
enhancer sequences are enriched for bound Nanog,
Sox2, Oct4, and the enhancer-related protein p300 [26].
As such, regulation of TE-derived enhancers and
lncRNAs by pluripotency TFs can result in the forma-
tion of positive-feedback loops, potentially bolstering
pluripotency networks [25, 26, 62]. Thus, in agreement
with other studies, Fort et al. demonstrated that specific
ERVs are major contributors to the stem cell transcriptome
and found a plethora of novel stem cell-associated ERV-
derived transcripts that await functional characterization,
in line with expectation that some of these lncRNAs will
be involved in the establishment and maintenance of pluri-
potency [70].
ERV expression dynamics during somatic cell
reprogramming
Domesticated TEs clearly play important functional roles
in stem cell biology. However, TE repression can shift as
cells transition through pluripotent states, as encoun-
tered during reprogramming. As a result, opportunistic
TEs may mobilize, cause insertional mutagenesis and,
potentially, compromise the integrity of reprogrammed
cells [32, 48, 71]. TE activity in stem cells therefore car-
ries risk as well as benefits for the host genome, along
with major incentives for TEs, given potential for early
Gerdes et al. Genome Biology  (2016) 17:100 Page 9 of 17embryonic retrotransposition events to be germline
transmitted. It follows that, although reprogramming
can broadly reactivate TEs, particularly those controlled
by TFs expressed dynamically during reprogramming
[16, 42], silencing is selectively re-established in the
resulting pluripotent cells, potentially ameliorating risk
to the host genome. For instance, although HERV-H and
HERV-K are both transcriptionally active during repro-
gramming, HERV-H is expressed in cultured iPSCs,
whereas the more recently mobile HERV-K family is si-
lenced [28] (Fig. 4b). This contrast is also found for
mouse iPSCs, where Mus type-D related retrovirus
(MusD) expression contrasts with intracisternal A-type
particle (IAP) silencing [32]. Importantly, more experi-
ments are required to confirm the generality of these ob-
servations, as technical considerations in iPSC generation
(e.g., reprogramming and culture conditions) can lead to
differences in TE expression between iPSC lines [71].
TE repression is dynamic during reprogramming. In a
high-resolution analysis of mouse and human iPSC lines,
Friedli et al. [32] found that most ERVs peaked in ex-
pression shortly before reprogramming was complete
and were then repressed in pluripotent cells. Broad TE
expression during somatic cell reprogramming may be
in itself important for the induction of the pluripotent
state. Ohnuki et al. [24] reported, for example, that
LTR7 elements (associated with HERV-H) are hyperacti-
vated by Oct4, Sox2, and Klf4 during reprogramming. In
the resultant iPSCs, however, LTR7 activity decreased toTable 2 Selected factors silencing ERVs in embryonic stem cells
Factor Relevant function in ESCs
Zfp809 KRAB zinc finger protein, recognizes PBS Pro and re
YY1 Yin-Yang 1 (YY1) is a zinc finger protein, initially bin
ERV LTRs (U3 region) and helps assemble Trim28/E
complex
SHIN Short heterochromatin inducing sequence initiates h
and transcriptional repression
Trim28 (Kap1, Tif1-β) Transcriptional co-repressor, acts as a bridge betwe
and other transcriptional repressors, mediates H3K9
Eset (Setdb1, Kmt1e) Histone methyltransferase, trimethylates H3K9 and
for HP1 binding
Sumo2 Sumoylation factor, post-translational sumoylation
enhances recruitment of Trim28 to proviral DNA
HP1 Heterochromatin protein 1, binding to Trim28 mig
for repression of transcription
Chaf1a Histone chaperone, deposits histone H3/H4 which
DNA for silencing, might execute different silencing
on different classes of ERVs
Asf1a/b Histone chaperones, components of the Chaf1a int
Atrx ATP-dependent helicase, establishes and maintains h
Daxx H3.3-specific chaperone, may facilitate H3.3-deposit
sequences, possible role in SHIN-silencing
ERV endogenous retrovirus, ESC embryonic stem cell, KRAB Krüppel-associated box,
zinc finger proteinlevels seen in hESCs and, notably, ectopic LTR7 hyper-
activity in iPSCs resulted in a differentiation-defective
phenotype [24]. Similarly, cumulative HPAT expres-
sion rises markedly during reprogramming and is di-
minished in iPSCs and, as for HPAT5, may influence
reprogramming efficiency [30]. Taken together, these
data indicate that TE hyperactivity is potentially dele-
terious to the host genome due to an elevated risk of
retrotransposition but may also be a requirement of
induced reprogramming.
ERV silencing in pluripotent states
The machineries responsible for ERV regulation in ESCs
are evidence of the complex relationships that can form
between TEs and their host genome. Broadly speaking,
to reduce the probability of retrotransposon-derived mu-
tagenesis, mammalian genomes target ERVs with DNA
methylation, heterochromatin-forming factors, transcrip-
tional repressor complexes, proviral silencing factors,
and post-transcriptional arrest or degradation of viral
RNAs (Table 2) [19, 20, 72]. Prominently, histone modi-
fications silence ERVs in ESCs [73–75] by making chro-
matin inaccessible to polymerases and transcription
factors [76], although this silencing in itself carries po-
tential for deleterious side effects when nearby genes are
also inadvertently repressed [77]. Moreover, some ERVs
are marked by H3K9me3 and H4K20me3 for repression
in ESCs but not in differentiated cells [6], suggesting
that this pathway is used for de novo establishment ofInteracting proteins Reference(s)




eterochromatin KRABZfps (likely) [93]
en KRAB-Zfps
me3 recruitment
KRABZfps, Eset, NuRD deacetylase
complex, HP1
[74, 86]
H4K20, crucial Trim28, HP1 [73]
of Trim28 Trim28 [72]
ht be important Trim28, Eset, Atrx [86, 89]
marks proviral
mechanisms
Eset, Kdm1a, Hdac1/2, Asf1a/b [72]
eractome Chaf1a [72]
eterochromatin Eset, Trim28 (both likely) [93]
ion on ERV Atrx [93, 95]
LTR long terminal repeat, SHIN short heterochromatin inducing sequence, Zfp
Gerdes et al. Genome Biology  (2016) 17:100 Page 10 of 17heterochromatin around ERV sequences [75, 78] or, al-
ternatively, is used to maintain repression already estab-
lished in oocytes [79, 80].
Even ERVs in accessible chromatin can be decisively
silenced by DNA methylation. In mice, de novo DNA
methylation is regulated by the canonical Zfp/Trim28/
Eset machinery [75]. Krüppel-associated box (KRAB)
zinc finger proteins (Zfps) play a major role in the initi-
ation of ERV silencing [81, 82]. Indeed, the number of
ERVs and Zfp genes in vertebrates are correlated,
suggesting coevolution [83]. As an example of the com-
plexity of Zfp-mediated retrovirus silencing, Zfp809
knockout induces the in vivo expression of Moloney
murine leukemia virus (MMLV)-like 30 (VL30) provirus
[84]. Zfp809 also binds to MMLV and initiates silencing
by recruiting Trim28 (also known as Kap1) [74, 85, 86].
Trim28 activity is enhanced by post-translational sumoy-
lation by Sumo2 [72, 87] and binds HP1, which is
thought to contribute to the ability of Trim28 to repress
transcription in the context of MMLV silencing [86, 88,
89]. Another Zfp, YY1, also binds to MMLV [90, 91]
and, together with Zfp809, is thought to recruit Trim28
to ensure a stably DNA-bound silencing complex [92].
In another example, KRAB Zfps have been shown to
trigger heterochromatin formation in IAP retrotranspo-
sons by binding to a short heterochromatin inducing
(SHIN) sequence, dependent on Eset and Trim28 [93],
enacting H3K9 and H4K20 trimethylation [73]. Chaf1a
facilitates deposition of these H3 and H4 variants and
also interacts with Eset [72]. Eset-mediated ERV silen-
cing is also important in mouse primordial germ cells
before the onset of de novo DNA methylation [80].
Hence, ERV silencing is enacted by a multilayered and
interleaved system that ensures robust and specific re-
pression of ERV families, subsets, and individual loci.
It follows that models explaining ERV silencing are
typically complex, which, at times, can lead to differing
conclusions. For instance, the SNF2-type chromatin re-
modeler Atrx is another crucial component for IAP si-
lencing that renders Eset-dependent heterochromatin
less accessible [93] and is likely to be recruited to IAPs
by Trim28 and Eset [93] (Fig. 5a). Interestingly, Atrx has
been reported to interact with the H3.3-specific
chaperone Daxx to facilitate H3.3 deposition at telo-
meric heterochromatin [94]. Yet, it is not clear if H3.3 is
required for ERV silencing, despite detection of H3.3
across ERV flanking regions and solo LTRs [95]. In gen-
eral, Sadic et al. [93] and Elsässer et al. [95] reached op-
posing conclusions with regards to H3.3 enrichment
around ERV sequences (Fig. 5b). One possible explan-
ation here is that Elsässer et al. used chromatin immu-
noprecipitation sequencing (ChIP-seq) to detect H3.3-
enriched regions across the entire mouse genome and
found a correlation between H3.3, H3K9me3, and ERVcoordinates. Sadic et al., on the other hand, used an
engineered reporter assay to measure ERV silencing
which, in H3.3 knockout cells, remained intact. Further
study is therefore required to resolve the place of H3.3
in models of ERV silencing. Overall, these and other ex-
amples of TE repression in pluripotent cells, such as the
silencing of nascent L1 and MMLV insertions in embry-
onic carcinoma derived cell lines [96, 97], reflect the extra-
ordinary efforts made by the host genome to orchestrate
silencing of currently and recently retrotransposition-
competent TEs during embryonic development.Endogenous L1 mobilization in mammalian
somatic cells
The early embryo is a viable niche for the generation of
potentially heritable retrotransposon insertions. In par-
ticular, L1 mobilization in human and rodent embryos
may drive somatic and germline mosaicism [98–101]
and, indeed, deleterious human L1 insertions transmit-
ted from mosaic parents to offspring have resulted in
sporadic genetic disease [101]. In vitro experiments have
likewise provided support for L1 mobilization occurring
in pluripotent cells [99–101] and, potentially, the pres-
ence of the L1 retrotransposition machinery being
required for preimplantation mouse embryo develop-
ment [102]. Human iPSCs and ESCs allow low-level
mobilization of an engineered L1 reporter [22, 48, 99].
Consistently, endogenous L1 promoter hypomethylation
and transcriptional activation have been observed in
iPSCs [32, 48, 71], as has induction of a primate-specific
L1 antisense peptide (ORF0p) that appears to increase
L1 mobility in stem cells [56] (Box 2). Endogenous de
novo L1 retrotransposition and mobilization of nonau-
tonomous Alu and SINE–VNTR–Alu (SVA) elements
have also been reported by Klawitter et al. [71] in several
iPSC lines, as well as an Alu insertion in a cultured
hESC line. L1 may, therefore, trans mobilize Alu and
other SINEs during development, an important finding
due to the high potential of SINEs to impact gene regu-
lation [12, 71, 103, 104]. Klawitter et al. estimated that
approximately one de novo L1 insertion occurred per
cell in human iPSCs. Strikingly, more than half of the
detected de novo L1 insertions were full length and thus
potentially able to mobilize further. Klawitter et al. also
observed extraordinary induction of L1 mRNA and pro-
tein expression after reprogramming. To speculate, nu-
merous L1 ribonucleoprotein particles (RNPs; Box 2)
could form as a result and be carried through iPSC cul-
ture and differentiation. This could enable L1-mediated
insertional mutagenesis in cells descending from those
where L1 expression originally occurred, as others have
considered for L1 RNPs arising in gametes and carrying















































































Fig. 5 Proposed models of de novo endogenous retrovirus (ERV) silencing in embryonic stem cells. a To initiate silencing, the Krüppel-associated
box (KRAB) zinc finger protein (Zfp) Zfp809 interacts with the proline primer binding site (PBS Pro) of some ERV families (e.g., Moloney murine
leukemia virus) [85] whereas other KRAB-Zfps bind to a short heterochromatin-inducing (SHIN) sequence found in intracisternal A-type particle
retrotransposons and other ERV families [93]. Subsequently, Trim28 is recruited by the Zfps [74, 86], assisted by binding of YY1 to the long
terminal repeat (LTR) and Trim28 [92]. Interaction with HP1 and sumolyation by Sumo2 are thought to contribute to transcriptional repression
mediated by Trim28 [72, 86, 89]. Eset also interacts with Trim28 and enables trimethylation of H3K9 and H4K20 [73]. The histone chaperone
Chaf1a, aided by Asf1a/b, marks proviral DNA for silencing by depositing histones H3 and H4 and interacts with Eset [72]. b Conflicting models of
ERV silencing by H3.3 deposition. The Atrx–Daxx complex is suggested to play an important role in SHIN-mediated silencing, which is H3.3-
independent. Here, Atrx is thought to promote ERV heterochromatin inaccessibility (left) [93]. However, Atrx–Daxx is also proposed to deposit
H3.3 and to interact with Trim28, followed by H3.3 being marked with H3K9me3 by Eset (right) [95]
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in the mouse germline [105, 106], their capacity to
mobilize during embryogenesis is less clear than for hu-
man L1. Quinlan et al., for instance, concluded de novo
retrotransposition in mouse iPSCs did not occur, or was
very rare [107], in contrast to results for human iPSCs
[22, 48, 71]. However, an earlier study found that engi-
neered L1 reporter genes mobilize efficiently in mouse
embryos [100]. Interestingly, the vast majority of engi-
neered L1 insertions in these animals were not heritable,
perhaps indicating retrotransposition later in embryo-
genesis [100]. Targeted and whole-genome sequencing
applied to mouse pedigrees has, conversely, revealed that
endogenous L1 mobilization in early embryogenesis is
relatively common and often leads to heritable L1 inser-
tions (SRR and GJF, unpublished data). PolymorphicERV and nonautonomous SINE insertions are also found
in different mouse strains [105, 106]. Although the de-
velopmental timing of these events is as yet unresolved,
we reason that they can occur in spatiotemporal con-
texts supporting L1 retrotransposition. It follows that
both human and mouse L1s, and probably mouse ERVs,
can mobilize in embryonic and pluripotent cells (Fig. 6),
as well as gametes. The resultant mosaicism can be dele-
terious to the host organism or their offspring [101],
again reinforcing the need for TE restraint during early
development.
Somatic L1 retrotransposition can also occur later in
development. Over the past decade, it has become
accepted that the mammalian brain, particularly cells of
the neuronal lineage, accommodate mobilization of






























Fig. 6 Long interspersed element-1 (L1) contributes to somatic mosaicism. L1 mobilizes in the brain and early embryo (left) and may, for example:
a insert into protein-coding exons; b influence neighboring genes by the spreading of repressive histone modifications, such as methylation (me);
c initiate sense or antisense transcription of neighboring genes, thereby creating new transcripts, including open reading frame 0 (ORF0) fusion
transcripts, using host gene provided splice acceptor sites, which are translated to fusion proteins; d generate DNA double-strand breaks via the
endonuclease activity of L1 ORF2p; and e lead to premature termination of host gene transcripts by providing alternative poly(A) signals
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neurogenesis is disputed [35, 36, 108, 109], this is largely
due to differences in the advanced techniques required
to discriminate genuine de novo L1 insertions and mo-
lecular artifacts arising during whole-genome amplifica-
tion of individual human neurons. This discrimination
can, broadly, be achieved quantitatively, by assuming
true-positives will accrue more DNA sequencing reads
than artifacts [108], or qualitatively, by analyzing the
junction DNA sequences between putative L1 insertions
and the flanking genome and excluding examples
inconsistent with target-site primed reverse transcription
[35]. Despite this debate, there is agreement that L1
mobilization occurs in the brain and can, for the most
part, be traced to neuronal precursor cells [35, 36, 109].
Remarkably, neuronal L1 insertions are distributed un-
evenly genome-wide and are enriched in neurobiological
genes and transcribed neuronal enhancers [34, 35]. Som-
atic L1 insertions oriented in sense to host genes, as the
configuration most likely to disrupt transcription [110,
111], are heavily depleted versus random expectation,
providing possible evidence of selection against theseevents during neurogenesis [35]. Concordantly, somatic
L1 insertions in neurobiological genes carry an elevated
chance of yielding a molecular phenotype in the brain,
especially provided the numerous routes by which L1 in-
sertions can profoundly modify gene structure and ex-
pression (Fig. 6) [12, 33, 77, 110, 112–118].
Neuronal L1 insertions impart no obvious evolution-
ary benefit as they cannot be transmitted to subsequent
generations. Thus, it is tempting to speculate that L1
activity is derepressed during neuronal commitment to
serve a biological purpose for the host organism, analo-
gous to the potential exaptation of ERV transcription
for pluripotency maintenance and following the ex-
ample of the vertebrate adaptive immune system, where
domesticated TEs mediate V(D)J recombination and
functional diversification through genomic mosaicism
[119]. Similarly, although individual somatic L1 inser-
tions in neurons are not inherited, it is plausible that
the cellular mechanisms and factors enabling their pro-
duction may undergo evolutionary selection [109].
While L1-mediated somatic mosaicism in neurons may
eventually be shown to have functional or behavioral
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ments are required to assess this hypothesis. Whether
perturbation of L1 regulation and retrotransposition in
the brain is connected to neurological disease is not yet
clear [35, 120–122]. The available evidence does, how-
ever, show conclusively that TE mobilization occurs
during embryogenesis and, in a more restricted fashion,
later in life.
Conclusions
The mammalian genome clearly strives to limit TE activ-
ity in pluripotent cells. The silencing mechanisms in-
volved are collectively complex and broadly potent and
yet are also capable of great specificity and dynamism in
targeting individual TE copies [17]. In this regard, ERVs
present two contrasting facets: firstly, the control mech-
anisms that have evolved to restrict ERV activity and,
secondly, the domestication of ERV sequences into pluri-
potency maintenance. Specific ERV families, such as
HERV-H and HERV-K, can provide binding sites for
pluripotency TFs, produce stem cell-specific protein-
coding and noncoding transcripts, and harbor new en-
hancers. Over time, these contributions have led to the
integration of ERVs into gene networks governing em-
bryogenesis and, surprisingly, independent ERV hyper-
activity appears to be a harbinger of pluripotent states.
Conversely, notwithstanding a need for more experimen-
tal data for murine ERVs, L1 appears to be the most suc-
cessful TE to mobilize in mammalian somatic cells and,
at the same time, is arguably less likely to impact their
phenotype than ERVs (Fig. 2). During human iPSC re-
programming, for example, L1 and ERVs can both be
broadly derepressed, but with divergent repercussions
for the host genome and providing different opportun-
ities to each TE family.
Why are TEs active, and apparently essential, in the
embryo? The relationship between TEs and the host
genome is often referred to as an evolutionary arms race
[123, 124]. A review specifically addressing the role of
TEs in pluripotency [14] refined this concept to more of
a genetic conflict of interest between ERVs and the host
genome, where exposure to retrotransposition was a ne-
cessary risk of the pluripotent state. The authors, as
others have done [28], also considered the possibility
that ERVs were active in stem cells by serendipity. Des-
pite their merits, each of these alternatives is contra-
dicted by several considerations. Firstly, L1 mobilization
appears to be far more common in the embryo than
ERV mobilization, despite ERV domestication being
overtly more useful to the host given the many ways
ERVs can reinforce pluripotency (Fig. 3). The benefits of
unleashing L1 and ERV activity do not seem then, in ei-
ther case, to be commensurate with the implied risk of
doing so. Secondly, ERVs are intrinsic to the pluripotentstate but are now almost, if not fully, immobile in
humans. Thirdly, different ERV families are centrally in-
volved in human and mouse pluripotency; convergent
evolution driven by the common environmental de-
mands of embryonic development, which are conserved
among mammals, is an improbable outcome of chance.
Here, time and scale are critical considerations: the vast
majority of new ERV insertions will be immediately si-
lenced but, as the retrotranspositional potential of an
ERV family is eliminated over time via mutations, pres-
sure to silence the associated LTRs may also diminish,
allowing them to regain their regulatory activity. Hence,
with sufficient time, distinct ERV families in different
species can ultimately come to occupy similar niches, in
pluripotency and elsewhere. TEs pervade mammalian
genomes and, as such, even the low probability of a de
novo ERV insertion immediately escaping silencing pre-
sents a reasonable overall chance of such events becom-
ing important to genome-wide regulation. This remains
true even if the ERV family is eventually immobilized.
Although not rejecting models based on serendipity or
conflict, we highlight that ERVs and other successful TE
families commonly arise as low copy number families
and then rapidly expand over generations. This scenario
could lead to TEs acquiring traits of early pioneers in a
potentially hostile genomic landscape. Two not necessar-
ily exclusive strategies can aid TE survival in this envir-
onment. One is stealth. For example, adaptation of the
L1 5′ promoter (Box 2) enables evasion of host genome
surveillance, leading to continuing L1 retrotransposition
during development. That most new L1 copies are 5′
truncated, and lack the canonical promoter, also reduces
their visibility to surveillance. Although this self-limits
the capacity of new L1 insertions to retrotranspose, it
also reduces pressure on the host genome to clamp
down on L1 activity. The other strategy is gaining ac-
ceptance by being useful. ERV promoters are repeatedly
found in pluripotency regulatory networks and may,
therefore, be intrinsic to the pluripotent state. In this
setting, efforts by the host genome to limit ERV activity
could be detrimental to pluripotency. As such, ERVs
may be able to propagate for longer than would be pos-
sible should the host engage in resolute inhibition. Im-
portantly, these strategies are predicated on embryonic
retrotransposition having potential for germline trans-
mission, i.e., carrying risk for host genome integrity, as
many studies have now found. Even after ERV families
are no longer capable of mobilization, their inherent
capacity for regulation, especially by solo LTRs, is
retained and provides a long-term evolutionary incentive
for the host genome to maintain at least one active TE
family, as almost all mammals do. As such, rather than
an arms race, conflict, or even symbiotic relationship, we
would propose that pioneer ERVs adopt peaceful survival
Gerdes et al. Genome Biology  (2016) 17:100 Page 14 of 17strategies and that intricate mechanisms for TE repres-
sion have evolved to allow the host genome to harness
those strategies over time, allowing some ERV families
to expand and, as witnessed in the embryo, securely
embed themselves by becoming indispensable. In advo-
cating this model, we emphasize that indispensability of
ERV-mediated regulatory effects in natural pluripotency
and embryogenesis in vivo is still an open question.
While difficult to pursue in humans, genetic knockout
or deletion of individual mouse ERVs or ERV families
implicated in pluripotency is possible [125] and, indeed,
ultimately necessary to demonstrate their functional im-
portance to the embryo.
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